Recruiting studies: Cyclophosphamide Reduced Dose

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative
Phase 2 · 3 location(s) · City of Hope Medical Center · NCT06042569 The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofet
Phase 1/Phase 2 · 2 location(s) · National Cancer Institute (NCI) · NCT05436418 Reduced Dose of Cyclophosphamide Combined With Standard Immunosuppressive Therapy to Treat Severe Aplastic Anemia
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06695741 To Study Lower Dose of Cyclophosphamide After Stem Cell Transplant for Blood Cancers
Phase 2 · 2 location(s) · Tata Memorial Centre · NCT07719946 Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment
Phase 3 · 1 location(s) · Shanghai Jiao Tong University School of Medicine · NCT06705062 Reduced ATG Plus Mini PTCy for GVHD Prophylaxis in Haplo-SCT
Phase 2 · 1 location(s) · Peking University People's Hospital · NCT06984536

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.